AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug
A long-speculated deal between Summit Therapeutics and AstraZeneca has finally come to fruition, but for a slice of the biotech instead of the whole pie. On Monday, the companies announced that AstraZeneca will invest $2 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.